NCT05253807 2025-08-05
FIGHT-210
Incyte Corporation
Phase 2 Completed
Clinical Trials
5 trialsNCT06551896 2024-08-13
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT05004974 2024-03-12
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Recruiting
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05287386 2022-03-18
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
The First Affiliated Hospital of Xiamen University
Phase 2 Unknown